Embodiments disclosed include systems, devices, and methods for analysis of samples containing particles used for gene delivery to determine a quality of the sample and/or an indication that the gene delivery particles are in a full, partial, and/or empty state. The present disclosure also relates to determining a protein and/or NA content in samples with known proportions of gene delivery particles in a full, partial, and/or empty state and based on the determination, establish a relationship between NA content and proportions of gene delivery particles in a full state. The present disclosure also relates to using such an established relationship to predict a proportion of the gene delivery particles in a full, partial, and/or empty state in test samples having the gene delivery particles in an unknown state.

Methods, systems and devices for detecting the presence of a pathogen, for example, a virus (e.g., SARS-CoV-2), or its molecular components, in health care-related samples and/or environmental samples are disclosed. An example system for improving detection of a pathogen includes biosensor device comprising a detection chip and at least one probe that specifically recognizes a pathogen, where the detection chip comprises a graphene field-effect transistor (FET) chip and the probe, which comprises an aptamer, specifically binds to a DNA, RNA, or protein associated with the pathogen.

An apparatus includes a surface acoustic wave (SAW) sensor. The SAW sensor includes a piezoelectric substrate. The SAW sensor also includes first and second interdigitating transistors over the piezoelectric substrate. The first interdigitating transistor is configured to convert an input electrical signal into an acoustic wave. The second interdigitating transistor is configured to convert the acoustic wave into an output electrical signal. The piezoelectric substrate is configured to transport the acoustic wave. The SAW sensor further includes a detection layer over the piezoelectric substrate and positioned at least partially between the first and second interdigitating transistors. The detection layer includes (i) antibodies configured to bind to one or more biological analytes and (ii) a hydrogel layer over the antibodies.

The present invention provides compositions and methods that can be used to determine a peptide signature for an antibody repertoire in a sample comprising multiple antibodies. The method can be used to characterize a phenotype in a sample, such as providing a diagnosis, prognosis or theranosis of a medical condition.

The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).

The present invention is directed to peptides for use in the detection of antibodies against SARS-CoV-2, which are indicative of past SARS-CoV-2 infections. Additionally, assays and methods of distinguishing patients having had a prior infection from those vaccinated patients are also provided. Additionally, vaccine compositions for use in eliciting anti-SARS-CoV-2 immune response are provided along with methods of producing antibodies and methods of eliciting an immune response.

The present invention relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2, and methods and uses thereof in the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19.

Aspects of the disclosure are directed to methods, systems, and compositions for detecting antibodies capable of binding to angiotensin II. Certain aspects comprise detection of antibodies capable of binding to angiotensin II in a sample from a subject, where the subject has or has had a coronavirus infection, such as a SARS-CoV-2 infection. Also disclosed are vaccine compositions comprising a portion of SARS-CoV-2 Spike protein, where such compositions do not induce generation of angiotensin II-binding antibodies.

The present disclosure is directed to isolated or recombinant antigen binding proteins, such as antibodies, which bind to coronavirus spike (S) protein receptor binding domain (RBD), including S protein RBD from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The present disclosure is also directed to the use of the isolated or recombinant proteins as therapeutic, prophylactic and/or diagnostic agents for respiratory conditions associated with coronavirus infection, such as infection by SARS-CoV-2. The present disclosure is also related to nucleic acid sequences which encode said antigen binding proteins and their expression in recombinant host cells.

Methods for the near real-time detection of airborne analytes using imprinted micelles and electrochemical cells are described. The methods demonstrate selectivity to the imprinted micelles over others that are of similar size and configuration and are compatible with airborne aerosol sampling techniques. The detection method can be used to monitor and detect any airborne analyte, including pathogens (such as SARS-CoV-2), toxins, proteins, organic molecules, inorganic particles, chemicals, explosive particles, and environmental pollutants.